

Tokyo, Japan) was cultured in Dulbecco's modified Eagle's medium with 15% FCS. The MAbs were prepared essentially as previously described (31, 32), with minor modifications. Briefly, BALB/c mice were primed intraperitoneally with 1–10 μg of purified VLPs (GI.1 Mc114, GI.5 Yokote1, GI.6 Nichinan, GII.3 Syd53, GIV Syd3, or GV NK24 VLPs) per mouse, in the presence of adjuvant. The mice received booster inoculations four times at 1 week intervals, the final injection of antigen being administered *i.v.* Three to four days after the final injection, the animals were killed and cells from their spleens fused with the myeloma cells. The culture medium of the hybridomas that resulted from successful fusions was screened for reactivity by ELISA. ELISA plates were coated with VLPs as described below. Positive hybridomas were cloned by limiting dilution and antibody-producing clones were grown and stored in liquid nitrogen until used for further tests. Finally, ascites fluid was prepared by injecting the hybridomas into pristane-primed mice and used to provide the MAbs for this study. The isotype and subclass of each MAb were determined by ELISA with anti-mouse subtype MAbs (Cappel Laboratories, West Chester, PA, USA) or an IC kit (IsoQuick, Sigma, Saint Louis, MO, USA).

All animal procedures conformed to the Animal Handling and Ethical Regulations of the University of Hyogo and the provisions of the Declaration of Helsinki. This research project was approved by the Ethics Committee of the University of Hyogo.

Enzyme-linked immunosorbent assay

An indirect ELISA, with slight modifications, was used to screen and characterize the MAbs (31). Briefly, 96-well microplates (Nunc-immune plate, Nunc, Roskilde, Denmark) were coated with 100 ng of VLPs/well in 50 μL of PBS (pH 7.2) overnight at 4°C. The plates were washed with TPBS and blocked with 5% skim milk in PBS for 1 hr at 37°C. The MAbs (ascites, appropriate dilution, 50–100 μL) were added and incubated for 1 hr at 37°C. After washing with TPBS, 50 μL of a 1:2000 dilution of HRPO-conjugated goat anti-mouse immunoglobulin G (IgG), IgM, or IgA (Cappel Laboratories) was added to each well and incubated for 1 hr at 37°C. After washing, 50 μL of OPD-H₂O₂ (0.5 mg of ortho-phenylenediamine/mL, 0.002% H₂O₂, 0.1 M citrate-phosphate buffer, pH 5.5) was added, incubated for 10–20 min, and the optical densities measured at 490 and 655 nm with a Microplate Reader (Model 550, Bio-Rad, Richmond, CA, USA).

To further characterize the epitopes recognized by these MAbs, a competitive indirect ELISA was performed as previously described (33, 34) with a slight modification. Briefly, VLP was used to coat 96-well microplates

overnight at 4°C at a concentration of 50–100 ng/well in PBS (pH 7.2). In separate tubes, MAbs at a concentration of 5–500 ng/mL (depending on the VLPs used for the coating) were added to decreasing concentrations of competitor VLP (10, 1, 0.1 and 0.01 $\mu\text{g}/\text{mL}$) in PBS (pH 7.2) containing 1% skim milk, and then incubated overnight at 4°C. As a control, MAb without competitor VLP was included in each plate. The VLP-coated plates were washed and blocked with 5% skim milk for 1 hr at 37°C, 100 μL of each of the VLP-MAb reaction mixtures was added to duplicate wells, and the plates were incubated for 2 hr at 37°C. The reactivity of the antibody to the competitors was expressed as B/B₀, where B is the amount of antibody bound to the coating antigen in the presence of the competitor, and B₀ is the amount in the absence of the competitor.

Sodium dodecyl sulfate–polyacrylamide gel electrophoresis

The VLPs (0.5–1 μg per track) were suspended in electrophoresis sample buffer containing 1% SDS, 10% 2-mercaptoethanol, 50 mM Tris-HCl (pH 6.8), 0.0025% phenol red, and 10% glycerol. The samples were boiled for 2 min, then subjected to 10% SDS-PAGE (catalog no. EMP-8020; 1 mm thick, 8 cm long, 7 cm wide; Iwaki, Tokyo, Japan) at a constant current of 20 mA for 1.5–2 hr. The gels were stained with 0.1% CBB (Sigma) or silver staining kit (Ez stain Silver, Atto, Tokyo Japan).

Immunoblotting

Western blotting analysis was performed as previously described (31, 35) with slight modifications. Briefly, after electrophoresis, the gel was transferred electrophoretically to a nitrocellulose membrane (0.45 μm pore size, Millipore, Bedford, MA, USA) in a semidry transfer (EPM-8460; Iwaki) at a constant current of 70 mA for 2–3 hr. The strips were prepared and incubated overnight at room temperature with the MAbs (ascites fluid) at a dilution of 1:500–1000. The blots were incubated with a 1:2000 dilution of HRPO-conjugated goat anti-mouse IgG, IgM, and IgA (Bio-Rad) for 1 hr at 37°C. The strips were soaked in a solution of DAB (0.5 mg/mL, 3'-diaminobenzidine, 0.001% H₂O₂, 50 mM Tris-HCl buffer, pH 6.0) to detect the antigen-antibody complexes on the strips.

Sequence analysis

To confirm the sequences of the panel of plasmids used in this study, nucleotide sequence analysis was performed with a Big Dye Terminator (version 3.1) Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Tokyo, Japan) and an automated sequencer, the 3130 Genetic Analyzer (Applied Biosystems). Nucleotide sequences were




Fig. 1. Electron micrographs of novel SaV VLPs. VLPs derived from (a) SaV GI.6 Nichinan, (b) GII.3 20082029, (c) GII.3 D1711, (d) GII.3 Kushiro5, (e) GII.3 Nayoro4, (f) GII.4 Kumamoto6, (g) GII.7 20072248 and (h) GIV Yakumo8 have diameters of 41–43 nm. Purified VLPs were stained with 4% uranyl acetate (pH 4) and examined by an electron microscope (TEM-1400; JOEL, Japan) operating at 80 kV. Scale bars = 100 nm.

assembled with the program Sequencher, version 4.10.1 (Gene Codes, Ann Arbor, MI, USA). Nucleotide and amino acid sequences were analyzed with GENETYX Mac software, version 16.0.4 (Genetyx, Tokyo, Japan).

RESULTS

Expression of novel human sapovirus virus-like particles

Sapovirus capsid proteins were expressed in an insect cell, Tn5, and VLPs were purified by CsCl equilibrium density gradient centrifugation as described in Materials and Methods. EM analysis of eight purified SaV VLPs from GI.6 Nichinan, GII.3 20082029, GII.3 D1711, GII.3 Kushiro5, GII.3 Nayoro4, GII.4 Kumamoto6, GII.7 20072248 and GIV Yakumo8 showed cuplike surface depressions and almost homologous particles with diameters of approximately 41–43 nm (Fig. 1). The morphology of these recombinant particles is very similar to those we have observed in previous studies (14, 16, 19, 20).

Isolation of sapovirus monoclonal antibodies

BALB/c mice were immunized intraperitoneally with purified SaV VLPs and their spleen cells fused with PAI myeloma cells. Sixty-five hybrid clones producing MABs were obtained from six different recombinant

human SaV VLPs from GI.1 Mc114, GI.5 Yokote1, GI.6 Nichinan, GII.3 Syd53, GIV Syd3 or GV NK24. Twenty-four MABs were obtained from mouse ascites and classified into five groups, according to their patterns of ELISA reactivity with 15 VLPs (GI.1 [$n = 1$], GI.5 [$n = 1$], GI.6 [$n = 1$], GII.2 [$n = 1$], GII.3 [$n = 6$], GII.4 [$n = 1$], GII.7 [$n = 1$], GIV [$n = 2$], and GV [$n = 1$]) (Table 1). The MABs were grouped as follows: MABs cross-reacting with all GI, GII, GIV and GV (group A, $n = 8$); GI-specific or type-specific MABs (group B, $n = 7$); GII-specific or type-specific MABs (group C, $n = 3$); GIV-specific MABs (group D, $n = 2$); and GV-specific MABs (group E, $n = 4$).

Monoclonal antibodies cross-reactive with heterologous genogroups and genotypes.

Eight group A MABs showed binding to all GI, GII, GIV and GV VLPs examined in this study, although their reactivity to each VLP was different. Four MABs (namely, 5C9, 1A1, 5C1 and 6C4) reacted consistently and strongly with VLPs from different genogroups and genotypes when the OD ratios between samples and PBS were greater than 10. On the other hand, another four MABs (8127, 6D3, 3D2 and 4G7) reacted either strongly or moderately (OD ratio: 5–9) with GI, GIV and/or GV VLPs, and weakly (OD ratio 1–4) with GII VLPs in ELISA (Table 1). Among these eight MABs, three (5C9, 1A1 and 8127) were further confirmed

Table 1. Reactivities of monoclonal antibodies with 15 SaV VLPs in ELISA

Group	MAb	Immunogen	Isotype	Reactivity ^a														
				GI ^b			GII							GIV			GV	
				1 ^c	5	6	2	3	3	3	3	3	3	4	7	1	1	1
Mc114	Yokote1	Nichinan	Mc10	C12	20082029	D1711	Syd53	Kushiro5	Nayoro4	Kumamoto6	20072248	Syd3	Yakumo8	NK24				
A	5C9	Nichinan	IgG1	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	1A1	Nichinan	IgG1	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	5C1	Nichinan	IgG1	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	6C4	Nichinan	IgM	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	8127	Yokote1	IgG1	+++	+++	+++	+	+	+	+	+	+	+	+	+	+	+	+++
	6D3	Nichinan	IgG1	++	+++	+++	++	+	+	+	NT	++	++	++	++	++	++	++
	3D2	Nichinan	IgG1	+	++	+++	++	+	+	+	++	NT	+	++	+	+	+	++
	4G7	Nichinan	IgG1	+	NT	+++	+	+	+	+	NT	+	+	+	+	+	+	+
B	616	Yokote1	IgG1	++	+++	++	-	-	-	-	-	-	-	-	-	-	-	-
	1325	Mc114	IgG1	++	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	5001	Mc114	IgG1	++	-	NT	-	-	NT	NT	-	NT	NT	NT	NT	-	NT	-
	4357	Mc114	IgG1	++	-	NT	-	-	NT	NT	-	NT	NT	NT	NT	-	NT	-
	627	Yokote1	IgG1	-	++	NT	-	-	NT	NT	-	NT	NT	NT	NT	-	NT	-
	7F8	Nichinan	IgM	-	-	++	-	-	-	-	NT	-	-	-	-	-	-	-
	1F2	Nichinan	IgM	-	-	++	-	-	-	-	NT	-	-	-	-	-	-	-
C	1803	Syd53	IgG3	-	-	-	++	++	++	++	++	++	++	++	++	-	-	-
	8083	Syd53	IgG3	-	-	NT	++	++	NT	NT	++	NT	NT	NT	NT	-	-	-
	1015	Syd53	IgG2b	-	-	-	-	++	++	++	++	++	+	-	-	-	-	
D	819	Syd3	IgG1	-	-	NT	-	-	NT	NT	-	NT	NT	NT	NT	++	++	-
	806	Syd3	IgG1	-	-	NT	-	-	NT	NT	-	NT	NT	NT	NT	++	++	-
E	1496	NK24	IgG1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+++
	155	NK24	IgG1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+++
	4971	NK24	IgG1	-	-	NT	-	-	NT	NT	-	NT	NT	NT	NT	-	NT	+++
	1052	NK24	IgG1	-	-	NT	-	-	NT	NT	-	NT	NT	NT	NT	-	NT	+++
	anti-SaV serum			+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	PBS			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

^aReactivities: +++, strong (OD ratio of sample/PBS > 10); ++, moderate (5–9); +, weak (1–4); -, negative (< 1); NT, not tested.

^bGenogroup

^cGenotype (22)




Fig. 2. SDS-PAGE of purified SaV VLPs and western blots. VLPs from (a, b) GI (GI.5 Yokote1) and (c, d) GI.6 Nichinan, GII (20072248), GIV (Yakumo8) or GV (NK24) were separated by SDS-PAGE. The proteins were stained with (a) CBB or transferred to a nitrocellulose sheet which was then incubated with (b) MAbs 8127, (c) 5C9 or (d) 1A1. Lane M, molecular mass markers (kDa).

by WB analysis to react with GI, GII, GIV and GV SaV VP1 with an apparent molecular mass of about 60 kDa (Fig. 2). These results indicate that SaV capsid protein carries at least one epitope common to GI, GII, GIV and GV SaV. Protein bands smaller than 60 kDa are likely truncated VP1 as previously described, though direct evidence is lacking (14).

Genogroup- or genotype-specific monoclonal antibodies

Seven group B MAbs reacted exclusively with GI VLPs, but not with any other VLPs from GII, GIV and GV SaVs. MAb 616 bound to three GI SaV VLPs (GI.1 Mc114, GI.5 Yokote1 and GI.6 Nichinan) in a genogroup-specific manner, whereas MAbs 1325, 5001, 4357, 627, 7F8 and 1F2 bound to VLPs in a genotype-specific manner (Table 1). Three group C MAbs (1803, 8083 and 1015) showed reactivity only with GII VLPs. MAb 1803 reacted to all GII VLPs (GII.2, -3, -4, and -7) examined, but not to GI, GIV and GV VLPs. On the other hand, MAb 1015 reacted with all GII.3 VLPs, but not with GII.2, GII.4, GII.7, GI, GIV and GV VLPs, demonstrating that this MAb is likely to be GII.3-specific (Table 1). Two group D MAbs (819 and 806) were specific to GIV (Syd3 and Yakumo8) VLPs and did not bind to GI, GII and GV VLPs. Four group E MAbs

(1496, 155, 4971 and 1052) were specific to GV VLPs (Table 1).

Epitopes recognized by cross-reactive monoclonal antibodies

Three MAbs classified as group A (5C9, 1A1 and 8127) had broad reactivity to VLPs derived from all human SaV genogroups (GI, GII, GIV and GV). The specificity of these MAbs was further examined by competitive ELISA. When GI.6 Nichinan VLP was used as the coating antigen, binding of MAb 5C9 was completely inhibited. In addition, binding of MAb 5C9 was similarly blocked by three heterotypic VLPs (GII.7 20072248, GIV Yakumo8 and GV NK24) (Fig. 3a). Similar results were obtained when GII.7 20072248 VLP was used as the coating antigen. Binding of MAb 5C9 was completely inhibited by homotypic GII.7 VLP and also by three heterotypic VLPs, GI.6 Nichinan, GIV Yakumo8 and GV NK24 (Fig. 3b). The results were similar when two other VLPs, GIV Yakumo8 and GV NK24, were used as the coating antigens (data not shown). Binding of MAb 1A1 to four VLPs (GI.6 Nichinan, GII.7 20072248, GIV Yakumo8 and GV NK24), as well as inhibition by homotypic and heterotypic VLPs was exactly the same as that of MAb 5C9 (Fig. 3c, d), suggesting these two MAbs (5C9 and 1A1) recognize a common epitope. On the other hand, binding of MAb 8127 to GI.5 Yokote1 and GV NK24 VLPs was different. Binding of MAb 8127 to GI VLP was strongly blocked by both homotypic GI VLP and heterotypic GV VLP (Fig. 3e) and binding to GV VLP was similarly inhibited by both homotypic GV VLP and heterotypic GI VLP (Fig. 3f). However, inhibition by two other competitor VLPs, GII.7 20072248 and GIV Yakumo8, was incomplete (Fig. 3e, f), demonstrating that the epitope recognized by MAb 8127 is different from that of MAbs 5C9 and 1A1.

DISCUSSION

In this study, we established 65 hybridoma cell lines from six mice immunized with six SaV VLPs, and characterized 24 MAbs in detail. These MAbs were classified into group A (MAbs broadly cross-reactive to all GI, GII, GIV and GV strains), and groups B–E (genogroup-specific or genotype-specific MAbs). We also obtained another 27 MAbs specific to particular strains: five to GI.1 Mc114, three to GI.5 Yokote1, five to GII.3 Syd3, five to GIV Syd3, and nine to GV NK24 (data not shown). In addition, 14 MAbs were positive by ELISA but negative by WB. We did not further characterize these 41 MAbs in this study.

Group A MAbs are broadly reactive to all GI, GII, GIV and GV SaV VLPs by both ELISA and WB (Table 1




Fig. 3. Competitive ELISA to differentiate epitope recognition. Microplates were coated with VLPs from (a) GI.6 Nichinan, (b) GII.7 20072248, (c) GIV Yakumo8, (e) GI.5 Yokote1, or (d, f) GV NK24. A reaction mixture of the various concentrations of the competitor VLPs and a MAb was added to the plates and binding of the MAb to the coated VLPs was measured as described in Materials and Methods. The competitor VLPs used in this experiments were ○, GI.6 Nichinan; ●, GI.5 Yokote1; X, GII.7 20072248; △, GIV Yakumo8; □, GV NK24. PBS(+) was used as a control without competitor. (a, b) MAbs 5C9, (c, d) 1A1 and (e, f) 8127 were incubated with the competitor VLPs.

and Fig. 2), indicating that cross-reactive epitope(s) is/are present on the SaV VP1 in these four genogroups. Based on the competition ELISA, the epitopes recognized by MAbs 5C9 and 1A1 seems to be common to them but different to that of MAb 8127 (Fig. 3). In ELISA, the reactivity of three MAbs (5C9, 1A1 and 5C1) was consistent and strong to GI, GII, GIV and GV VLPs. MAbs 8127 reacted strongly with GI and GV VLPs but weakly with

GII and GIV VLPs (Table 1). The different reactivities between different genogroups of SaV VP1 partly supports the possibility of distinct epitopes for MAbs 5C9, 1A1 and MAb 8127.

The X-ray crystallographic structure of human SaV has not been reported, but cryo-electron microscopy has revealed structural similarities between human SaV VLPs and NoV VLPs (8). X-ray crystallographic studies of

Sapovirus monoclonal antibody




Fig. 4. Amino acid alignment of nine representative SaV VP1 protein sequences. Predicted amino acid sequences of GI.6 Nichinan, GI.1 Mc114, GI.5 Yokote1, GII.2 Mc10, GII.3 Nayoro4, GII.4 Kumamoto6, GII.7 20072248, GIV Yakumo8 and GV NK24 VP1 are shown. Asterisks indicate conserved amino acids among the 15 SaV strains used in this study. Dots indicate identical amino acid residues. The extents of S and P domains indicated in the above sequences were inferred from published information about NoV VP1 (8).

human NoV VLPs has revealed that NoV VP1 has the following two principal domains: a shell (S) domain, and a protrusion (P) domain that is further divided into three subdomains called N-terminal P1, P2 and C-terminal P1 (36). The NoV S domain and P1 subdomains are highly and moderately conserved, respectively. The P2 domain is highly variable among NoV strains (8, 37), this domain is likely to be the key determinant of strain specificity and antigenicity (37). MAbs broadly cross-reactive with NoV VLPs have been described (31, 34, 38–41), these studies demonstrating that the epitopes are located in the S domain (40, 41) or C-terminal P1 domain (38, 42) in the NoV VP1.

Hyper-immune sera raised against human SaV VLPs has revealed distinct antigenicity among different human SaV genogroups and genotypes (15–17, 20, 21, 23, 43). Genogroup- and genotype-specific MAbs (group B–E MAbs) were also isolated in this study. These MAbs will be useful tools for further study of the antigenic determinant of human SaV. Amino acid sequence homology of VP1 among the 15 SaV strains is 28.1% (data not shown). Despite these significant amino acid sequence variations among different genogroups and genotypes of SaV VP1, the predicted S domain is relatively more conserved than the P2 domains (Fig. 4). From the amino acid sequence alignment, the antigenic determinant is likely to be present in the predicted P2 domain in human SaV, and common epitopes may occur in the predicted S or P1 domains, although further experiments are necessary.

In conclusion, we have established a panel of MAbs that are reactive with human SaV VLPs in a broad, genogroup-specific or genotype-specific manner. The broadly reactive MAbs are of particular interest as possible reagents for the development of human SaV detection or diagnostic assays (i.e., ELISA or immunochromatography) in clinical settings, because ELISA using hyperimmune sera shows narrow reactivity to specific genogroups (15–17, 21, 23, 43). Because human SaVs have also been detected in clams (25,44), oysters (45) and environmental water (46–51), broadly reactive MAbs may also become valuable tools for concentrating or removing human SaVs from food or environmental specimens.

ACKNOWLEDGMENTS

We thank Akira Iwakiri (Miyazaki Prefectural Institute for Public Health and Environment Science), Setsuko Iizuka (Shimane Prefectural Institute for Public Health and Environment Science), Seiya Harada (Kumamoto Prefectural Institute for Public Health and Environment Science) and Setsuko Ishida (Hokkaido Institute of Public Health) for providing SaV positive stool specimens. We also thank to Michiyo Kataoka (Department of Pathology, National In-

stitute of Infectious Diseases) for her excellent assistance with electron microscopy. This work was supported in part by grants for Research on Food Safety, as well as Research on Emerging and Re-emerging Infectious Diseases, from the Ministry of Health, Labour, and Welfare of Japan.

DISCLOSURE

The authors declare no financial or commercial conflicts of interest.

REFERENCES

1. Harada S., Okada M., Yahiro S., Nishimura K., Matsuo S., Miyasaka J., Nakashima R., Shimada Y., Ueno T., Ikezawa S., Shinozaki K., Katayama K., Wakita T., Takeda N., Oka T. (2009) Surveillance of pathogens in outpatients with gastroenteritis and characterization of sapovirus strains between 2002 and 2007 in Kumamoto Prefecture, Japan. *J Med Virol* **81**: 1117–27.
2. Iturriza-Gomara M., Elliot A.J., Dockery C., Fleming D.M., Gray J.J. (2009) Structured surveillance of infectious intestinal disease in pre-school children in the community: 'The Nappy Study'. *Epidemiol Inf* **137**: 922–31.
3. Monica B., Ramani S., Banerjee I., Primrose B., Iturriza-Gomara M., Gallimore C.J., Brown D.W., Fathima M., Moses P.D., Gray J.J., Kang G. (2007) Human caliciviruses in symptomatic and asymptomatic infections in children in Vellore, South India. *J Med Virol* **79**: 544–51.
4. Pang X.L., Lee B.E., Tyrrell G.J., Preiksaitis J.K. (2009) Epidemiology and genotype analysis of sapovirus associated with gastroenteritis outbreaks in Alberta, Canada: 2004–2007. *J Infect Dis* **199**: 547–51.
5. Svraka S., Vennema H., van der Veer B., Hedlund K.-O., Thorhagen M., Siebenga J., Duizer E., Koopmans M. (2010) Epidemiology and genotype analysis of emerging sapovirus-associated infections across Europe. *J Clin Microbiol* **48**: 2191–8.
6. Chiba S., Sakuma Y., Kogasaka R., Akihara M., Horino K., Nakao T., Fukui S.J. (1979) An outbreak of gastroenteritis associated with calicivirus in an infant home. *J Med Virol* **4**: 249–54.
7. Chiba S., Sakuma Y., Kogasaka R., Akihara M., Terashima H., Horino K., Nakao T. (1980) Fecal shedding of virus in relation to the days of illness in infantile gastroenteritis due to calicivirus. *J Inf Dis* **142**: 247–9.
8. Chen R., Neill J.D., Noel J.S., Hutson A.M., Glass R.I., Estes M.K. (2004) Inter- and intragenus structural variations in caliciviruses and their functional implications. *J Virol* **78**: 6469–79.
9. Farkas T., Zhong W.M., Jing Y., Huang P.W., Espinosa S.M., Martinez N., Morrow A.L., Ruiz-Palacios G.M., Pickering L.K., Jiang X. (2004) Genetic diversity among sapoviruses. *Arch Virol* **149**: 1309–23.
10. Katayama K., Miyoshi T., Uchino K., Oka T., Tanaka T., Takeda N., Hansman G.S. (2004) Novel recombinant sapovirus. *Emerg Infect Dis* **10**: 1874–6.
11. Hansman G.S., Oka T., Takeda N. (2008) Sapovirus-like particles derived from polyprotein. *Virus Res* **137**: 261–5.
12. Oka T., Yamamoto M., Miyashita K., Ogawa S., Katayama K., Wakita T., and Takeda N. (2009) Self-assembly of sapovirus recombinant virus-like particles from polyprotein in mammalian cells. *Microbiol Immunol* **53**: 49–52.
13. Guo M., Qian Y., Chang K.O., Saif L.J. (2001) Expression and self-assembly in baculovirus of porcine enteric calicivirus capsids

- into viruslike particles and their use in an enzyme-linked immunosorbent assay for antibody detection in swine. *J Clin Microbiol* **39**: 1487–93.
14. Hansman G.S., Natori K., Oka T., Ogawa S., Tanaka K., Nagata N., Ushijima H., Takeda N., Katayama K. (2005) Cross-reactivity among sapovirus recombinant capsid proteins. *Arch Virol* **150**: 21–36.
 15. Hansman G.S., Natori K., Ushijima H., Katayama K., Takeda N. (2005) Characterization of polyclonal antibodies raised against sapovirus genogroup five virus-like particles. *Arch Virol* **150**: 1433–7.
 16. Hansman G.S., Oka T., Sakon N., Takeda N. (2007) Antigenic diversity of human sapoviruses. *Emerg Infect Dis* **13**: 1519–25.
 17. Hansman G.S., Saito H., Shibata C., Ishizuka S., Oseto M., Oka T., Takeda N. (2007) Outbreak of gastroenteritis due to sapovirus. *J Clin Microbiol* **45**: 1347–9.
 18. Numata K., Hardy M.E., Nakata S., Chiba S., Estes M.K. (1997) Molecular characterization of morphologically typical human calicivirus Sapporo. *Arch Virol* **142**: 1537–52.
 19. Oka T., Hansman G.S., Katayama K., Ogawa S., Nagata N., Miyamura T., Takeda N. (2006) Expression of sapovirus virus-like particles in mammalian cells. *Arch Virol* **151**: 399–404.
 20. Oka T., Miyashita K., Katayama K., Wakita T., Takeda N. (2009) Distinct genotype and antigenicity among genogroup II sapoviruses. *Microbiol Immunol* **53**: 417–20.
 21. Farkas T., Deng X., Ruiz-Palacios G., Morrow A., Jiang X. (2006) Development of an enzyme immunoassay for detection of sapovirus-specific antibodies and its application in a study of seroprevalence in children. *J Clin Microbiol* **44**: 3674–9.
 22. Oka T., Mori K., Iritani N., Harada S., Ueki Y., Iizuka S., Mise K., Murakami K., Wakita T., Katayama K. (2012) Human sapovirus classification based on complete capsid nucleotide sequences. *Arch Virol* **157**: 349–52.
 23. Jiang X., Cubitt D.W., Berke T., Zhong W.N., Dai X., Nakata S., Pickering L.K., Matson D.O. (1997) Sapporo-like human caliciviruses are genetically and antigenetically diverse. *Arch Virol* **142**: 1813–27.
 24. Iwakiri A., Ganmyo H., Yamamoto S., Otao K., Mikasa M., Kizoe S., Katayama K., Wakita T., Takeda N., Oka T. (2009) Quantitative analysis of fecal sapovirus shedding: identification of nucleotide substitutions in the capsid protein during prolonged excretion. *Arch Virol* **154**: 689–93.
 25. Iizuka S., Oka T., Tabara K., Omura T., Katayama K., Takeda N., Noda M. (2010) Detection of sapoviruses and noroviruses in an outbreak of gastroenteritis linked genetically to shellfish. *J Med Virol* **82**: 1247–54.
 26. Ishida S., Yoshizumi S., Miyoshi M., Ikeda T., Okui T., Katayama K., Takeda N., Oka T. (2008) Characterization of sapoviruses detected in Hokkaido, Japan. *Jpn J Infect Dis* **61**: 504–6.
 27. Hansman G.S., Katayama K., Maneekarn N., Peerakome S., Khamrin P., Yonusin S., Okitsu S., Nishio O., Takeda N., Ushijima H. (2004) Genetic diversity of norovirus and sapovirus in hospitalized infants with sporadic cases of acute gastroenteritis in Chiang Mai, Thailand. *J Clin Microbiol* **42**: 1305–07.
 28. Li T.C., Takeda N., Miyamura T., Matsuura Y., Wang J.C., Engvall H., Hammar L., Xing L., Cheng R.H. (2005) Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus. *J Virol* **79**: 12999–3006.
 29. Hansman G.S., Takeda N., Katayama K., Tu E.T., McIver C.J., Rawlinson W.D. (2006) Genetic diversity of sapovirus in children, Australia. *Emerg Infect Dis* **12**: 141–3.
 30. Guntapong R., Hansman G.S., Oka T., Ogawa S., Kageyama T., Pongsuwanna Y. (2004) Norovirus and sapovirus infections in Thailand. *Jpn J Infect Dis* **57**: 276–8.
 31. Kitamoto N., Tanaka T., Natori K., Takeda N., Nakata S., Jiang X., Estes M.K. (2002) Cross-reactivity among several recombinant calicivirus virus-like particles (VLPs) with monoclonal antibodies obtained from mice immunized orally with one Type of VLP. *J Clin Microbiol* **40**: 2459–65.
 32. Kohler G., Milstein C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* **256**: 495–7.
 33. Hale A.D., Tanaka T., Kitamoto N., Ciarlet M., Jiang X., Takeda N., Brown D.W.G., Estes M.K. (2000) Identification of an epitope common to genogroup I Norwalk-like viruses. *J Clin Microbiol* **38**: 1656–60.
 34. Hardy M.E., Tanaka T., Kitamoto N., White L.J., Ball J.M., Jiang X., Estes M.K. (1996) Antigenic mapping of the recombinant Norwalk virus capsid protein using monoclonal antibodies. *Virology* **217**: 252–62.
 35. Towbin H., Staehelin T., Gordon J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc Natl Acad Sci USA* **76**: 4350–4.
 36. Prasad B.V., Hardy M.E., Dokland T., Bella J., Rossmann M.G., Estes M.K. (1999) X-ray crystallographic structure of the Norwalk virus capsid. *Science* **286**: 287–90.
 37. Hansman G.S., Natori K., Shirato-Horikoshi H., Ogawa S., Oka T., Katayama K., Tanaka T., Miyoshi T., Sakae K., Kobayashi S., Shinohara M., Uchida K., Nakurai S., Shinozaki K., Okada M., Seto Y., Kamata K., Nagata N., Tanaka K., Miyamura T., Takeda N. (2006) Genetic and antigenic diversity among noroviruses. *J Gen Virol* **87**: 909–19.
 38. Shiota T., Okame M., Takahasi S., Khamrin P., Takagi M., Satou K., Masuoka Y., Yagyu F., Shimizu Y., Kohno H., Mizuguchi M., Okitsu S., Ushijima H. (2007) Characterization of a broadly reactive monoclonal antibody against norovirus genogroups I and II: recognition of a novel conformational epitope. *J Virol* **81**: 12298–306.
 39. Tanaka T., Kitamoto N., Jiang X., Estes M.K. (2006) High efficiency cross-reactive monoclonal antibody production oral immunization with recombinant Norwalk virus-like particles. *Microbiol Immunol* **50**: 883–8.
 40. Yoda T., Terano Y., Suzuki Y., Yamazaki K., Oishi I., Kuzuguchi T., Kawamoto H., Utagawa E., Takino K., Oda H., Shibata T. (2001) Characterization of Norwalk virus GI specific monoclonal antibodies generated against *Escherichia coli* expressed capsid protein and the reactivity of two broadly reactive monoclonal antibodies generated against GII capsid towards GI recombinant fragments. *BMC Microbiol* **1**: 24.
 41. Yoda T., Suzuki Y., Terano Y., Yamazaki K., Sakon N., Kuzuguchi T., Oda H., Tsukamoto T. (2003) Precise characterization of norovirus (Norwalk-like virus)-specific monoclonal antibodies with broad reactivity. *J Clin Microbiol* **41**: 2367–71.
 42. Parker T.D., Kitamoto N., Tanaka T., Hutson A.M., and Estes M.K. (2005) Identification of genogroup I and genogroup II broadly reactive epitopes on the norovirus capsid. *J Virol* **79**: 7402–9.
 43. Hansman G.S., Guntapong R., Pongsuwanna Y., Natori K., Katayama K., Takeda N. (2006) Development of an antigen ELISA to detect sapovirus in clinical stool specimens. *Arch Virol* **151**: 551–61.
 44. Hansman G.S., Oka T., Okamoto R., Nishida T., Toda S., Noda M., Sano D., Ueki Y., Imai T., Omura T., Nishio O., Kimura H., Takeda

- N. (2007) Human sapovirus in clams, Japan. *Emerg Infect Dis* **13**: 620–2.
45. Ueki Y., Shoji M., Okimura Y., Miyota Y., Masago Y., Oka T., Katayama K., Takeda N., Noda M., Miura T., Sano D., Omura T. (2010) Detection of Sapovirus in oysters. *Microbiol Immunol* **54**: 483–6.
46. Hansman G.S., Sano D., Ueki Y., Imai T., Oka T., Katayama K., Takeda N., Omura T. (2007) Sapovirus in water, Japan. *Emerg Infect Dis* **13**: 133–5.
47. Haramoto E., Katayama K., Phanuwat C., Ohgaki S. (2008) Quantitative detection of sapoviruses in wastewater and river water in Japan. *Lett Appl Microbiol* **46**: 408–13.
48. Iwai M., Hasegawa S., Obara M., Nakamura K., Horimoto E., Takizawa T., Kurata T., Sogen S., Shiraki K. (2009) Continuous presence of noroviruses and sapoviruses in raw sewage reflects infections among inhabitants of Toyama, Japan (2006 to 2008). *Appl Environ Microbiol* **75**: 1264–70.
49. Kitajima M., Oka T., Haramoto E., Katayama H., Takeda N., Katayama K., Ohgaki S. (2010) Detection and genetic analysis of human sapoviruses in river water in Japan. *Appl Environ Microbiol* **76**: 2461–7.
50. Kitajima M., Haramoto E., Phanuwat C., Katayama H. (2011) Genotype distribution of human sapoviruses in wastewater in Japan. *Appl Environ Microbiol* **77**: 4226–9.
51. Sano D., Preze-Stautu U., Guix S., Pinto R.S., Miura T., Okabe S., Bosch A. (2011) Quantification and genotyping of human sapoviruses in the Llobregat River catchment, Spain. *Appl Environ Microbiol* **77**: 1111–4.

ノロウイルス感染症



本村和嗣

国立精神・神経医療研究センター トランスレーショナルメディカルセンター 臨床開発部先端診断技術開発室室長
国立感染症研究所病原体ゲノム解析研究センター

大石和徳

国立感染症研究所感染症情報センター センター長

ノロウイルスは、わが国において毎年秋冬季に流行する、感染性胃腸炎の原因ウイルスです¹⁾²⁾。わが国では2000年代以降、感染性胃腸炎の原因ウイルスの第1位になっています。最近では、2006～07年に世界中で大流行となりました。

経口摂取後、小腸（空腸、回腸）上皮細胞に感染し、40～48時間の潜伏時間を経て発症します³⁾。ヒトに対しては、発熱、嘔吐、下痢などの症状がおきますが、致死的ではなく、その多くは数日の経過で自然に回復します。

ノロウイルスの特徴は、ウイルスのなかでは小さい部類に属し、物理的に安定性が高く、たいへん感染力が強いことです。米国のボランティア研究では、ウイルス粒子が口腔内に10～100個入るだけで感染が成立することが報告されています。よって、人の密集する閉鎖空間では集団食中毒が頻繁に発生します。食品産業、医療施設、高齢者施設、教育施設、米国ではクルージング客船内での発生が報告されており⁴⁾、その結果、甚大な被害をもたらします。現代社会は、航空機、車、電車などの輸送網や経済網が高度に発達しています。ノロウイルスに汚染された物資やヒトが移動することで、国内はもとより大陸を超えての感染拡大が示唆されます。

本稿では、ノロウイルス感染症に関する、現時点でのわれわれの見解を紹介します。

新型 GII.4 株の検出

.....


ノロウイルスは、カプシド遺伝子配列の類似性をもとに、Group I～Vの五つに分類されています⁵⁾。このなかで、Group IIの中の4型（以下 GII.4）株は、1990年代後半以降、少なくとも4回（1995/96、2002/03、2004/05、2006/07）、世界的な大流行をきたしたことが報告されています。これらの流行では、例外なく GII.4新変異株が出現していました。

わが国では、流行するノロウイルスの実態調査の一環として、2006年よりノロウイルスのゲノム全長の塩基配列情報を蓄積しています。全国の衛生研究所と国立感染症研究所（ウイルス第二部と病原体ゲノム解析研究センター）が協力し「Norovirus Surveillance Group of Japan」を立ち上げ、全国各地で発生したノロウイルスの全ゲノム情報の収集と解析を実施しています。


われわれは、2006年から09年春のあいだに日本で流行したノロウイルス GII.4株のゲノム全長の塩基配列（ $n=199$ ）をもとに、近接接合法による系統樹解析を行いました。この解析により、この間、①遺伝情報の異なる7種類の GII.4亜株が日本で流行したこと（図1A）、②そのなかでも特定の株（2006b亜株）が、3シーズンにわたって日本国内で

図1 わが国で流行したノロウイルスの進化系統樹とGII.4亜株の年次推移

A.



B.



A : 2006 ~ 09 年にわが国で流行したノロウイルス全長ゲノム配列の分子進化系統樹解析
B : 日本における GII.4 亜株の年次推移

[文献 7 より図を改変]

大流行したこと (177/199; 約89%) (図 1 A), などが明らかとなりました。

2006b 亜株は、同時期に、ヨーロッパ、香港、オーストラリアでも大規模な流行の原因となっていたことがわかりました⁵⁾。その理由として、①抗原性の変化、つまりウイルス粒子のいちばん外側にあるカプシドタンパク質に、過去の流行株と比較して、特徴的なアミノ酸変異が存在することがわかりました⁵⁾。すなわち、ヒトの抗体が認識する抗原認識部位が大きく変化したことで、ヒトが持っている抗体が機能しなかったと考えられます。さらに、②病原性が強い、③ウイルスの複製・増殖能が高い、ことなども考えられます。

しかし、ヒトに感染するノロウイルスは細胞増殖系が確立されておらず、疾患モデル動物も開発されていないため、これらの仮説を証明することができません。よって、2006b 亜株がなぜ大流行をきたし、その後も流行を形成する主要な株であるのか、よくわかって

いません。


新型 GII.4 株の流行の動態

.....

次に、同定された 7 種の GII.4 亜株の検出頻度の年次推移を提示します (図 1 B)。わが国では、ノロウイルスが大流行した 2006/07 秋冬期に、2006b 亜株がそれまでの流行株 (2004/05 亜株) と入れ替わって全国規模で大流行し、その後も全国各地の流行の原因となったことがわかりました。また、2006b 亜株は、2005/06 秋冬期にも、限局的ではあるが日本国内に存在していたこともわかりました。このことから、2006~07 年にかけて、2006b 亜株が従来の流行株と入れ替わって世界的流行 (パンデミック) をひきおこしたことが明らかとなりました。

2006b 亜株は、その後 2007/08~2008/09 秋冬期にもひきつづき優勢な変異株として国内に流行していますが、2006/07 秋冬期に比べ

図2 2007年以降に出現した4種のGII.4新亜株のゲノム構造



ると、流行の規模は徐々に縮小しています(図1B)。2007/08秋冬期に新たなGII.4変異亜株(2007aと2007b)、2008/09秋冬期にも新たなGII.4変異亜株(2008aと2008b)が出現していました。しかしながら、これらの4種はいずれも、局地的かつ一過性の流行にとどまっていた。

2007年以降に出現したGII.4新亜株の特徴


.....

複数の異なる解析アプローチ(bootscanning plots法, 探索的系統分析法, 情報部位分析法)により, われわれの検出したGII.4亜株の全ゲノム構造を詳細に調べました。興

味深いことに, 2007年以降に出現した4種のGII.4新亜株2007a, 2007b, 2008a, 2008bは, いずれも直近に流行したノロウイルスGII.4亜株間のキメラウイルスであることがわかりました⁹⁾。これらのウイルスはすべて共通のゲノム組み換え点をもち, いずれもORF1/ORF2の境界領域に統計学的に有意と判定される推定ゲノム組み換え点が存在していました(図2)。

ORF1の遺伝子群の機能についてはいまだ不明ですが, おもにウイルスの複製・増殖にかかわると推測されています。一方, ORF2はウイルス粒子の外殻(カプシドタンパク質)を構成する遺伝子で, 抗原部位になります。起源の異なるORF1とORF2が組み合わ

図3 2007年以降に出現した3種のGII.4新亜株のカプシドタンパク質構造



破線で囲った部分は組織血液型抗原結合部位。2007b, 2008b 亜株の ORF2 配列は、2006b 亜株の ORF2 配列と同じであるために、2006b 亜株のカプシド立体構造解析図を掲載した

さることで、感染能力、増殖能力にすぐれ、免疫から逃避する能力がすぐれたウイルスが出現し、ヒト集団内で流行を保持しているのではないかと推測しています。

実際に、2007年以降に出現した4種のGII.4新亜株について、カプシドタンパク質における特徴的アミノ酸の配置を調べたところ、4種すべて最外殻領域に存在していることがわかりました(図3)。すなわち、抗原性が変化したウイルスであることが示唆されました。

医療施設でのノロウイルス感染 予防対策

日本では秋冬期に流行しますので、とくに11月～3月に嘔吐、下痢症が出た場合はノロウイルスではないかと考え、迅速に判断して、感染が拡がらないように、医療従事者や施設スタッフの方はマスクを着用したり、手指消毒することが重要です。嘔吐物には0.1%ぐらいの次亜塩素酸をかけて処理をします。入院患者さんが布団に嘔吐した場合は、処理後スチームアイロンで高熱処理をすることも勧められます。

近年、イムノプロットの迅速診断キットが開発されました。本キットを用いれば、迅速に診断することができます。しかし、病院、

施設によっては迅速診断キットがないところもありますので、症状から迅速にスタッフが判断し、それ以上感染が拡大しないように対応することが重要です。

ノロウイルス感染症の制御法開発

ノロウイルスの治療薬はまだ開発されていませんが、米国ではワクチンが開発されており、現在、臨床試験中です。途中経過の成績は、感染阻止率が20～25%、重症化を防ぐ率は50～60%でした。よって、およそ8割の人たちには何らかの恩恵があると思われます。ノロウイルスは、致死性の高いウイルスではありませんが、腸管免疫形成が未熟な小児、免疫力が低下している高齢者、基礎疾患のある人では重症化する可能性があるため、ワクチン接種対象になると考えられます。

*

ヒト社会において、ノロウイルスには日々膨大な数の変異ウイルスが発生していると推察されます。カプシドタンパク質最外殻領域に多数の変異をもち、抗原性が大きく変化したウイルスが出現すれば、ヒト社会の中で感染が拡がりやすいと考えられます。

今後、全長ゲノム配列情報の収集継続、次代のゲノム解析手法、血清疫学的手法などの

さまざまな解析アプローチにより、ノロウイルス流行の仕組みについて理解を深め、成果をもとに流行を制御する手段を開発していきたいと考えています。

〈参考文献〉

- 1) Okada M, Ogawa T, Kaiho I, Shinozaki K : Genetic analysis of noroviruses in Chiba Prefecture, Japan, between 1999 and 2004. J Clin Microbiol 43(9) : 4391-4401, 2005
- 2) Ozawa K, Oka T, Takeda N et al : Norovirus infections in symptomatic and asymptomatic food handlers in Japan. J Clin Microbiol 45(12) : 3996-4005, 2007
- 3) Estes MK, Prasad BV, Atmar RL : Noroviruses everywhere : Has something changed? Curr Opin Infect Dis 19(5) : 467-474, 2006
- 4) Zheng DP, Ando T, Fankhauser RL et

al : Norovirus classification and proposed strain nomenclature. Virology 346(2) : 312-323, 2006

- 5) Motomura K, Oka T, Yokoyama M et al : Identification of monomorphic and divergent haplotypes in the 2006-2007 norovirus GII/4 epidemic population by genomewide tracing of evolutionary history. J Virol 82(22) : 11247-11252, 2008
- 6) Motomura K, Yokoyama M, Oka T et al : Divergent evolution of norovirus GII/4 by genome recombination over 2006-2009 in Japan. J Virol 84(16) : 8085-8097, 2010
- 7) 本村和嗣, 横山 勝, 岡 智一郎ほか : ノロウイルスのゲノム解析と流行発生のしくみ. 日本感染症学雑誌 86(5) : 563-568, 2012

[もとむら・かずし／感染症学]

[おおいし・かずのり／感染症学]

からだの科学267

BACK NUMBER

年4回3,6,9,12月の27日発売

2010 AUTUMN

大腸の病気のすべて

日比紀文／編

●慶應義塾大学院医学部内科(消化器)教授

食物の“終着駅”である大腸は、発達した神経網が取り囲む複雑な器官でもある。大腸の発するさまざまな危険信号を読み取るには。

◆好評発売中／定価1,600円(税別)／B5判

●バックナンバーには数に限りがございます。書店または、直接小社ウェブサイトなどでお早めにお求めください。

●PART.1 大腸のA to Z

大腸疾患の多様性と最近の動向／大腸の構造とはたらき／気になる大腸の症状／大腸の病気はなぜおこるのか

●PART.2 大腸の異常を見つけ出す

便潜血反応検査／注腸X線造影検査／CT・MRI検査／超音波検査／内視鏡検査

●PART.3 大腸の病気を治療する

潰瘍性大腸炎／クローン病／腸結核／赤痢アメーバ／虚血性大腸炎／薬剤性腸炎／感染性腸炎／放射線性腸炎／大腸憩室炎／大腸がん／大腸ポリープ／消化管ポリープ／過敏性腸症候群／便秘／虫垂炎／小児の大腸疾患／痔核

●PART.4 大腸をいたわる

大腸にやさしい生活習慣／食事療法のコツ／プロ・プレバイオティクスをうまく活用する／大腸がん患者のQOL

〒170-9474 東京都豊島区南大塚3-12-4 TEL : 03-3987-8621 FAX : 03-3987-8590 日本評論社
ご注文は日本評論社サービスセンターへ TEL : 049-274-1780 FAX : 049-274-1788 <http://www.nippon.co.jp/>

Whole-genome analysis of two bovine rotavirus C strains: Shintoku and Toyama

Junichi Soma,¹ Hiroshi Tsunemitsu,² Takeshi Miyamoto,³ Goro Suzuki,¹ Takashi Sasaki¹ and Tohru Suzuki²

Correspondence

Tohru Suzuki

tohru_suzuki@affrc.go.jp

¹Research and Development Section, Institute of Animal Health, JA Zen-noh (National Federation of Agricultural Cooperative Associations), Chiba 285-0043, Japan

²Viral Disease and Epidemiology Research Division, National Institute of Animal Health, National Agriculture and Food Research Organization, Ibaraki 305-0856, Japan

³Toyama Prefectural Tobu Livestock Hygiene Service Center, Toyama 939-3536, Japan

Rotavirus C (RVC) has been detected frequently in epidemic cases and/or outbreaks of diarrhoea in humans and animals worldwide. Because it is difficult to cultivate RVCs serially in cell culture, the sequence data available for RVCs are limited, despite their potential economical and epidemiological impact. Although whole-genome sequences of one porcine RVC and seven human RVC strains have been analysed, this has not yet been done for a bovine RVC strain. In the present study, we first determined the nucleotide sequences for five as-yet underresearched genes, including the NSP4 gene, from a cultivable bovine RVC, the Shintoku strain, identified in Hokkaido Prefecture, Japan, in 1991. In addition, we elucidated the ORF sequences of all segments from another bovine RVC, the Toyama strain, detected in Toyama Prefecture, Japan, in 2010, in order to investigate genetic divergence among bovine RVCs. Comparison of segmental nucleotide and deduced amino acid sequences among RVCs indicates high identity among bovine RVCs and low identity between human and porcine RVCs. Phylogenetic analysis of each gene showed that the two bovine RVCs belong to a cluster distinct from human and porcine RVCs. These data demonstrate that RVCs can be classified into different genotypes according to host species. Moreover, RVC NSP1, NSP2 and VP1 amino acid sequences contain a unique motif that is highly conserved among rotavirus A (RVA) strains and, hence, several proteins from bovine RVCs are suggested to play important roles that are similar to those of RVAs.

Received 8 August 2012

Accepted 4 October 2012

INTRODUCTION

Rotavirus, one of major enteric pathogens of humans and other animals, is currently divided into eight species (A–H) on the basis of serological and genomic analyses (Estes & Kapikian, 2007; Matthijnssens *et al.*, 2012). The viral genome consists of 11 dsRNA segments encoding six structural proteins (VP1–4, VP6 and VP7) and five or six non-structural proteins (NSP1–6) (Jiang *et al.*, 1996). The viral particle is composed of three concentric layers. The outer capsid consists of two structural proteins, VP4 and VP7, which contain neutralization antigens. The inner capsid consists of the structural protein VP6. The core (inner layer) consists of VP2, the major inner core protein, VP1, the RNA-dependent RNA polymerase, and VP3, the

viral capping enzyme. The NSPs are known to be involved in viral replication, transcription, cellular pathology and morphogenesis (Estes & Kapikian, 2007).

Rotavirus C (RVC) was first identified in swine as a causative agent of diarrhoea in the 1980s (Saif *et al.*, 1980; Bohl *et al.*, 1982). Subsequently, several reports showed an association between porcine RVC and diarrhoea in nursing, weaning and post-weaning pigs (Sigolo de San Juan *et al.*, 1986; Morin *et al.*, 1990; Saif & Jiang, 1994; Kim *et al.*, 1999). To date, RVCs have been detected in humans, cows, ferrets and dogs (Rodger *et al.*, 1982; Torres-Medina, 1987; Tsunemitsu *et al.*, 1991; Chang *et al.*, 1999; Otto *et al.*, 1999; Mawatari *et al.*, 2004). Human RVCs have been detected not only exclusively in children under 3 years old, but also in all age groups including adults in many countries (Peñaranda *et al.*, 1989; Kuzuya *et al.*, 1998; Matsumoto *et al.*, 1989; Qiao *et al.*, 1999; Nilsson *et al.*, 2000; Adah *et al.*, 2002; Castello *et al.*, 2002; Mwenda *et al.*, 2003; Sánchez-Fauquier *et al.*, 2003; Phan *et al.*, 2004; Schnagl *et al.*, 2004; Rahman *et al.*, 2005; Abid *et al.*, 2007;

The GenBank/EMBL/DDBJ accession numbers for the bovine RVC sequences determined in this study are AB738402–AB738417, as detailed in Fig. 1.

Three supplementary tables are available with the online version of this paper.

Esona *et al.*, 2008; Gabbay *et al.*, 2008; Medici *et al.*, 2009; Mitui *et al.*, 2009; Luchs *et al.*, 2011; Moon *et al.*, 2011). However, the prevalence of RVC in gastroenteric disease of children was reported to be relatively low, in spite of the global distribution of the virus (Mackow, 1995). Apart from RVC infections in humans, a high prevalence of antibodies in cattle and pigs (47–56 and 93–97%, respectively) was detected in the United States and Japan (Tsunemitsu *et al.*, 1992). In contrast, another epidemiological study done in the United States showed that the detection rate of RVC in faecal samples from both diarrhoeic calves and adult cows using an RT-PCR method was very low (Chang *et al.*, 1999). Hence, there are discrepancies between previous reports and, furthermore, the potential zoonotic and economic impact of RVC in cows remains unclear because of the limited genetic data available for bovine RVCs.

Whole-genome analysis is beneficial for molecular characterization and understanding of the evolution of the pathogen. It is also useful for monitoring gene reassortment and interspecies transmission between different viral strains (Matthijssens *et al.*, 2008a, b, 2010; McDonald *et al.*, 2009). Recently, a classification system for rotavirus A (RVA) was developed to differentiate all segments into genotypes (Matthijssens *et al.*, 2008b). However, whole-genome analysis is to be preferred because of the difficulty in adapting RVCs to cell-culture propagation. To date, the full-genome sequence from one porcine RVC strain, Cowden, and several human RVC strains have been analysed, but those from bovine strains have not been fully elucidated (Mackow, 1995; Chen *et al.*, 2002; Yamamoto *et al.*, 2011). The bovine RVC strain Shintoku was isolated from four dairy cows (aged 28–41 months) affected with severe diarrhoea at a farm in Hokkaido Prefecture, Japan, in 1991 (Tsunemitsu *et al.*, 1991). Another bovine RVC strain, Toyama, was detected in dairy cows with sporadic diarrhoea in Toyama Prefecture, Japan, in 2010. To our knowledge, of several bovine RVCs, only the Shintoku strain could be serially propagated and maintained in a rhesus monkey kidney cell line (MA104) (Kusanagi *et al.*, 1992).

Genomic sequences of the bovine RVC Shintoku strain have already been determined for the VP3, VP4, VP6, VP7, NSP3 and NSP5 genes (Jiang, *et al.*, 1992, 1993; Tsunemitsu *et al.*, 1996). Sequence analyses of VP6 genes from bovine RVCs have been performed on only a few strains isolated in the United States (WD534tc) and Japan (Shintoku and Yamagata strains) (Jiang *et al.*, 1992; Chang *et al.*, 1999; Mawatari *et al.*, 2004). In addition, phylogenetic analyses of VP6 and VP7 genes indicate that the Shintoku and Yamagata strains belong to the same cluster, which is genetically distinct from human and porcine RVCs, whilst the WD534tc strain is classified into a porcine RVC cluster on the basis of genetic analysis of VP6 (Mawatari *et al.*, 2004). It therefore remains unclear whether there is genetic diversity among bovine RVC strains, since no other reports have appeared of the detection of RVCs from cattle. In order

to verify the genetic divergence among bovine RVCs, whole-genome data of bovine RVC strains other than the Shintoku strain would need to be accumulated.

In the present study, we attempted to determine the nucleotide sequences of the five underresearched genes (NSP1, NSP2, NSP4, VP1 and VP2) from the Shintoku strain and the ORF sequences of all 11 RNA segments from another bovine RVC strain, designated Toyama. Moreover, phylogenetic analysis of individual segments was also performed to establish a genetic classification among RVCs from different host species and to investigate genetic diversity among bovine RVCs.

RESULTS AND DISCUSSION

When nucleotide sequences of individual RVC segments were aligned, each sequence at the 5'- and 3'-ends was highly conserved (Kobayashi *et al.*, 2003). In fact, the VP6 gene of the Shintoku strain was detected and analysed using a set of primers designed on the basis of 5'- and 3'-terminal sequences from the human RVC Bristol strain (Jiang *et al.*, 1992). Consequently, RT-PCR with several pairs of primers, designed by reference to both ends of individual segments from the human RVC Bristol strain and/or the porcine RVC Cowden strain, was used to determine the full-length nucleotide sequences of NSP1, NSP2, VP1 and VP2 from the bovine RVC Shintoku strain (Table S1, available in JGV Online). Because the nucleotide sequences at both ends of the NSP4 gene, which has enterotoxigenic potential, were different between the Shintoku and Bristol strains, only the ORF sequence of the Shintoku NSP4 gene could be elucidated (see Table 2). In addition, ORF sequences of the remaining segments, except for NSP4, VP6 and VP7, of another bovine RVC strain, Toyama, were determined using a set of primers designed by reference to those of the Shintoku strain (Tables S1 and S2). The sizes of the 11 RNA segments as well as the sizes of the 11 ORFs of the two bovine RVC strains, in addition to those of human and porcine RVC strains, are summarized in Table 1. The lengths of the deduced amino acid sequences of NSP2, NSP3, VP1, VP6 and VP7 from the bovine RVCs were identical to those of human RVCs. NSP1 and VP3 from the bovine RVCs were one or two amino acids longer than those of human RVCs. On the other hand, bovine RVC NSP4, NSP5, VP2 and VP4 were shorter than their human RVC homologues.

Nucleotide and deduced amino acid sequence identities of the ORFs of individual genes among bovine RVC strains and between human and porcine RVC strains are shown in Tables 2 and S3. The sequences of corresponding segments were highly conserved among bovine RVCs (88.7–98.4% identity at the nucleotide level; 94.7–100% identity at the amino acid level). Throughout the 11 gene segments, the bovine RVCs exhibited relatively low sequence identities to human RVCs (57.6–82.1% at the nucleotide level; 54.7–89.1% at the amino acid level) and porcine RVCs (56.5–82.6% at the

Table 1. Full lengths of nucleotide and deduced amino acid sequences for individual genes among RVCs

Strain	NSP1		NSP2		NSP3		NSP4		NSP5	
	nt	aa	nt	aa	nt	aa	nt	aa	nt	aa
Shintoku	1273	395	1037	312	1350	402	ND	146	719	209
Toyama	ND	395	ND	312	ND	402	ND	146	ND	209
Bristol	1270	394	1037	312	1350	402	613	150	730	212
BK0830	1270	394	1037	312	1350	402	613	150	730	212
BS347	1270	394	1037	312	1350	402	613	150	730	212
OH567	1270	394	1037	312	1350	402	613	150	730	212
v508	1270	394	1037	312	1350	402	613	150	730	212
Wu82	1270	394	1037	312	1350	402	613	150	730	212
YNR001	1270	394	1037	312	1350	402	613	150	730	212
Cowden	1235	393	995	312	1348	402	613	150	693	210

Strain	VP1		VP2		VP3		VP4		VP6		VP7	
	nt	aa	nt	aa	nt	aa	nt	aa	nt	aa	nt	aa
Shintoku	3309	1090	2727	881	2166	695	2253	733	1352	395	1063	332
Toyama	3309	1090	ND	881	ND	695	2253	733	1352	395	1063	332
Bristol	3309	1090	2736	884	2166	693	2283	744	1353	395	1063	332
BK0830	3309	1090	2736	884	2166	693	2283	744	1353	395	1063	332
BS347	3309	1090	2736	884	2166	693	2283	744	1353	395	1063	332
OH567	3309	1090	2736	884	2166	693	2283	744	1353	395	1063	332
v508	3309	1090	2736	884	2166	693	2283	744	1353	395	1063	332
Wu82	3309	1090	2736	884	2166	693	2283	744	1353	395	1063	332
YNR001	3309	1090	2736	884	2166	693	2283	744	1353	395	1063	332
Cowden	3290	1082	2736	884	2145	692	2246	736	1352	395	1063	332

ND, Not determined (see text).

nucleotide level; 60.7–91.6% at the amino acid level). Of the 11 segments, NSP4 exhibited the lowest identity between bovine and other RVCs (56.5–59.7% at the nucleotide level; 54.7–62.7% at the amino acid level). In contrast, NSP2, VP1, VP2 and VP6 sequences were relatively conserved between bovine and other RVCs (>78% at the nucleotide level; >83% at the amino acid level). Moreover, the VP6 and VP7 nucleotide sequences of the Yamagata strain, which was detected in Japan in 2004, showed high identity to the Shintoku strain. In contrast, the phylogenetic tree based on partial sequences of VP6 genes from bovine RVCs detected in South Korea (positions 1095–1303) indicated that bovine RVCs were more closely related to porcine RVCs (Park *et al.*, 2011). In addition, genetic analysis of the RVC VP7 gene revealed that the WD534tc strain is genetically more closely related to the porcine RVC Cowden strain than to either the Shintoku or Yamagata strain (Chang *et al.*, 1999). These data suggest that bovine RVCs that are distributed widely in the world have wide diversity, but bovine RVCs in Japan may have originated from a common ancestor and then co-circulated around Japan.

Phylogenetic analyses of the 11 segments of the two bovine RVC strains were performed in comparison with those of several human and porcine strains. The Shintoku and Toyama strains belong to the same cluster, which is distinct from human and porcine RVCs on all segments (Fig. 1).

Subsequently, a genetic classification of each RVC segment was carried out on the basis of a cut-off value estimated according to the definitions of a previous report (Yamamoto *et al.*, 2011; see Methods). The cut-off values for genotyping of individual genes are summarized in Table 2. In the tree of the RVC VP7 gene, the Shintoku and Toyama strains were grouped into genotype G2 on the basis of the previous genetic classification (Martella *et al.*, 2007). In the genotyping of the RVC VP4 gene, the two bovine RVCs were classified into genotype P[3], whilst the human and porcine RVCs were grouped into genotypes P[2] and P[1], respectively. For the NSP3, NSP5, VP3 and VP6 genes, the two bovine RVCs were assigned to genotypes T3, H3, M4 and I3, respectively, on the pre-existing genotype classification (Yamamoto *et al.*, 2011). Phylogenetic analysis of the genes encoding NSP1, NSP2, NSP4, VP1 and VP2 indicated the presence of new genotypes harbouring the bovine RVCs, provisionally defined as A3, N3, E3, R3 and C3.

The presence of divergent or conserved regions in all segments among RVCs and between them and RVAs and/or RVBs was analysed by alignment of deduced amino acid sequences. Consequently, several motifs in NSP1, NSP2 and VP1 were highly conserved among RVAs, other RVCs and some RVBs (Fig. 2). In comparing NSP1 amino acid sequences from the two bovine RVCs with those of RVAs, a

Table 2. Identities of individual genes at the nucleotide level among RVCs

Nucleotide sequences of the bovine RVC strains, Shintoku and Toyama, were compared with one another or among three strains including the Yamagata strain in the case of VP6 and VP7. In addition, sequences of the two bovine RVC strains were also compared with human and porcine RVC strains as shown in Fig. 1.

Gene segment	Host	n	Nucleotide sequence identity (%)			Cut-off (%)
			Human	Porcine	Bovine	
NSP1	Human	10	92.8–99.9	66.3–67.8	66.3–67.7	74
	Porcine	1			73.2–73.7	74
	Bovine	2			96.0	74
NSP2	Human	10	93.7–100	85.2–88.0	80.6–82.1	89
	Porcine	1			82.5–82.6	89
	Bovine	2			98.4	89
NSP3	Human	10	92.6–99.8	76.3–78.2	77.5–79.2	80
	Porcine	1			77.3–77.7	80
	Bovine	2			97.2	80
NSP4	Human	13	94.6–99.8	68.8–70.3	57.6–59.7	71
	Porcine	1			56.5–57.9	71
	Bovine	2			93.2	71
NSP5	Human	10	92.0–99.5	76.0–76.8	74.6–75.9	79
	Porcine	1			78.1–78.5	79
	Bovine	2			95.3	79
VP1	Human	8	94.4–99.7	85.1–85.6	79.7–80.7	86
	Porcine	1			80.2–80.7	86
	Bovine	2			94.7	86
VP2	Human	9	94.5–99.8	82.7–83.3	78.8–79.3	84
	Porcine	1			80.2–80.4	84
	Bovine	2			95.9	84
VP3	Human	8	83.6–99.3	81.9–85.3	76.7–79.1	86
	Porcine	1			78.0–78.2	86
	Bovine	2			94.2	86
VP4	Human	13	95.4–99.7	71.9–72.7	70.3–70.9	77
	Porcine	1			75.9–76.3	77
	Bovine	2			97.0	77
VP6	Human	13	94.2–100	81.4–84.0	78.8–82.4	–
	Porcine	1			78.7–95.3	–
	Bovine	4			77.9–98.0	–
VP6 (exceptWD534tc)	Human	13	94.2–100	81.4–84.0	78.8–81.6	85
	Porcine	1			78.7–80.8	85
	Bovine	3			94.0–98.0	85
VP7	Human	23	88.4–99.6	69.4–83.7	68.8–74.6	84
	Porcine	4			71.8–80.9	84
	Bovine	3			88.7–92.4	84

common zinc-binding motif at the N-terminal domain, highly conserved in RVAs, was observed. This motif is known to be involved in evasion of the innate immune response to virus infection through binding to interferon regulatory factor 3 (IRF3) (Graff *et al.*, 2002). Therefore, the presence of the zinc-binding motif in bovine RVC NSP1 suggests that it is also involved in regulation of the host immune system, in the same manner as NSP1 from RVAs. The histidine triad motif (H $\phi\phi\phi$ H $\phi\phi$) of NSP2, which is important for NTPase activity, is highly conserved in RVAs, RVBs and other RVCs (Carpio *et al.*, 2004; Suzuki *et al.*, 2012). The fact that the bovine RVC NSP2 also possesses the

histidine triad motif suggests that the motif is essential for the viral replication process among different species of rotaviruses. Moreover, the amino acid sequences of the VP1 gene from the two bovine RVCs contain the consensus motif of the RNA polymerase that is highly conserved among RNA viruses (Cohen *et al.*, 1989; Nagashima *et al.*, 2008). This finding suggests that the product of the bovine RVC VP1 gene functions as an RNA-dependent RNA polymerases, as is the case for other rotaviruses.

In conclusion, our study demonstrates that bovine RVCs can be classified into genotypes distinct from human and porcine RVCs according to genetic relatedness and the




Fig. 1. Phylogenetic trees for all individual segments from RVCs. The dendrograms were reconstructed by the neighbour-joining method with the MEGA 5 program. Percentages of bootstrap support (from 1000 replicates) are indicated at each node; values less than 70% are not indicated. B, Bovine; H, human; P, porcine. GenBank accession numbers are also shown. Genotypes are given to the right.

species of origin. The fact that the two bovine RVCs identified in Japan are genetically more closely related to each another suggests that bovine RVCs derived from a common origin are circulating among farms throughout Japan. The data presented here will expand molecular information and aid the progress of genetic analysis of RVCs.

METHODS

Viruses. The RVC Shintoku strain was propagated and maintained in MA104 cells in our laboratory according to a method described previously (Tsunemitsu *et al.*, 1991). The RVC Toyama strain originated from faecal samples of diarrhoeic dairy cows in 2010. Viral RNA was extracted from culture fluid or 10% faecal suspension diluted with PBS using TRIzol LS (Invitrogen) according to the manufacturer's instructions.

RT-PCR and sequencing. The full-length nucleotide sequences of four genes, NSP1, NSP2, VP1 and VP2, and the ORF sequence of the NSP4 gene from the Shintoku strain were amplified and sequenced by

RT-PCR using primers originally designed to correspond to genes of the human RVC Bristol and/or porcine RVC Cowden strains (Table S1). The ORF sequences of the 11 RNA segments from the Toyama strain were amplified and sequenced by RT-PCR using primers designed to correspond to the genes of the Shintoku strain, in addition to primers used in the analysis of five unidentified genes of the Shintoku strain (Table S2). RT-PCRs were carried out using a OneStep RT-PCR kit (Qiagen) according to the following conditions: 50 °C for 30 min and 95 °C for 15 min, followed by 35 cycles of 94 °C for 1 min, 48 °C for 1 min and 72 °C for 2 min, and then a final extension at 72 °C for 10 min. The products were sequenced using a BigDye Terminator version 3.1 cycle sequencing kit on an automated ABI Prism 3130 Genetic Analyzer (Applied Biosystems).

Sequence data were aligned by the CLUSTAL W method using the MEGALIGN 7.2 program of the Lasergene software (DNASTAR). Phylogenetic analyses were conducted using MEGA version 5 (Tamura *et al.*, 2011). Genetic distances were calculated using the Poisson correction parameter at the nucleotide level and Kimura's two-parameter correction at the amino acid level (Matthijssens *et al.*, 2008b). Phylogenetic trees were constructed with 1000 bootstrap replicates (Saitou & Nei, 1987).

In order to classify individual genotypes of each of the bovine RVC segments, a cut-off value was determined according to the methods described by Yamamoto *et al.* (2011). Briefly, the cut-off value for genotyping of each gene segment was defined as a value that is slightly higher than the maximum sequence identity at the nucleotide level between human and animal RVCs, because these RVCs were grouped into different clusters in the phylogenetic dendrograms as shown in Fig. 1. The values for genetic classification among RVCs including the two bovine RVC strains, Shintoku and Toyama, are summarized in Table 2.




Fig. 2. Partial amino acid sequence alignments of NSP1 (a), NSP2 (b) and VP1 (c) from human RVA (Wa), simian RVA (SA11), human RVC (Bristol), porcine RVC (Cowden), two bovine RVCs (Shintoku and Toyama), human RVB (IC-008) and bovine RVB (DB176). Dots indicate amino acids identical to those of the human RVA Wa strain. (a) The zinc-finger motif and cysteine- and histidine-rich regions are shaded. (b) A histidine triad motif, an active site of nucleotide triphosphatase, is boxed. (c) The consensus motif of RNA polymerase (SG, T, N, T, GDD) is shaded.

ACKNOWLEDGEMENTS

This study was supported by a partial grant from the National Institute of Animal Health. We thank A. Miyazaki and K. Kuga for their helpful comments and discussions.

REFERENCES

- Abid, I., Guix, S., Aouni, M., Pintó, R. & Bosch, A. (2007). Detection and characterization of human group C rotavirus in the pediatric population of Barcelona, Spain. *J Clin Virol* **38**, 78–82.
- Adah, M. I., Wade, A., Oseto, M., Kuzuya, M. & Taniguchi, K. (2002). Detection of human group C rotaviruses in Nigeria and sequence analysis of their genes encoding VP4, VP6, and VP7 proteins. *J Med Virol* **66**, 269–275.
- Bohl, E. H., Saif, L. J., Theil, K. W., Agnes, A. G. & Cross, R. F. (1982). Porcine pararotavirus: detection, differentiation from rotavirus, and pathogenesis in gnotobiotic pigs. *J Clin Microbiol* **15**, 312–319.
- Carpio, R. V., González-Nilo, F. D., Jayaram, H., Spencer, E., Prasad, B. V., Patton, J. T. & Taraporewala, Z. F. (2004). Role of the histidine triad-like motif in nucleotide hydrolysis by the rotavirus RNA-packaging protein NSP2. *J Biol Chem* **279**, 10624–10633.
- Castello, A. A., Argüelles, M. H., Villegas, G. A., Olthoff, A. & Glikmann, G. (2002). Incidence and prevalence of human group C rotavirus infections in Argentina. *J Med Virol* **67**, 106–112.